Search research articles
Contact Us
Filters
Showing results (11-20 of 91) with videos related to
Page
of 10
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2022
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
Kendra DeBusk, Chiemeka Ike, Nicolas Lindegger, et al.
Future Oncology (London, England)
|
May 28, 2021
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer
Naomi Rm Schwartz, Kendra DeBusk, Andres Forero-Torres, et al.
The Oncologist
|
August 3, 2012
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies
Andres Forero-Torres, Michelle Fanale, Ranjana Advani, et al.
Oncotargets and Therapy
|
May 12, 2018
A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
Todd M Bauer, Manish R Patel, Andres Forero-Torres, et al.
Future Oncology (London, England)
|
August 31, 2021
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis
Kendra DeBusk, Shaun Abeysinghe, Adrian Vickers, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, Patrice Lee, Janelle Taylor, et al.
The New England Journal of Medicine
|
November 5, 2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
Anas Younes, Nancy L Bartlett, John P Leonard, et al.
Breast Cancer Research and Treatment
|
September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity
Angelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma
Ranjana Advani, Andres Forero-Torres, Richard R Furman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma
Christos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 91) with videos related to
Sort By:
Page
of 10
Journal of Managed Care & Specialty Pharmacy
|
May 27, 2022
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
Kendra DeBusk, Chiemeka Ike, Nicolas Lindegger, et al.
Future Oncology (London, England)
|
May 28, 2021
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer
Naomi Rm Schwartz, Kendra DeBusk, Andres Forero-Torres, et al.
The Oncologist
|
August 3, 2012
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies
Andres Forero-Torres, Michelle Fanale, Ranjana Advani, et al.
Oncotargets and Therapy
|
May 12, 2018
A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
Todd M Bauer, Manish R Patel, Andres Forero-Torres, et al.
Future Oncology (London, England)
|
August 31, 2021
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis
Kendra DeBusk, Shaun Abeysinghe, Adrian Vickers, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, Patrice Lee, Janelle Taylor, et al.
The New England Journal of Medicine
|
November 5, 2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
Anas Younes, Nancy L Bartlett, John P Leonard, et al.
Breast Cancer Research and Treatment
|
September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity
Angelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma
Ranjana Advani, Andres Forero-Torres, Richard R Furman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma
Christos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Page
of 10